RESUMO
@# Objective: To evaluate the long-term clinical efficacy and follow-up of dendritic cell (DC) vaccines in combination with cytokine-induced killer cell (CIK) treatment in metastatic renal cell carcinoma. Methods: From January 2011 to December 2013, 29 patients with metastatic renal cell carcinoma (pathologically confirmed as renal clear cell carcinoma) were treated by DC vaccines-CIK at the Department of Hematopoietic Stem Cell Transplantation, the Fifth Medical Center of Chinese PLA General Hospital. The 29 patients included 24 male and 5 female, with a median age of 57(32-81) years old. Mature DC vaccine was obtained by gene transfection technology and CIK cells were obtained by i n v i t r o culture; and DC vaccine-CIK was infused back to patients through lymphatic drainage area and vein by each course. Twelve patients received first line treatment, 6 patients received second line treatment after the disease progression by targeted drug therapy or cytokine therapy, and 11 patients received third-linetreatment or above. The long-term clinical efficacy and overall survival rate were evaluated. Results: The median follow-up time was 5 (1-7) years. Treatment cycle was over 2 (2-23) cycles. One case (3.4%) achieved complete remission, 9 cases (31%) achieved partial responses, 13 cases (44.8%) demonstrated stable disease over 3 months and 6 patients (20.7%) developed progressive disease. The objective response rate was 34.4%,and the disease control rate was 79.2%. Stable disease for more than one year realized in 19 cases (65.5%). The 1-, 3- and 5-year survival rates were 93.1% (27/29), 65.5% (20/29) and 51.7% (15 / 29), respectively. Neither the median progression-free survival (PFS) nor the median survival time was achieved. No adverse reactions above grade 3 were observed during treatment. Conclusion: DC vaccines-CIK therapy for the treatment of metastatic renal cell carcinoma is affirmative; it achieved good disease control and long-term survival with controllable safety, and prolonged the survival time for advanced renal cell carcinoma patients.
RESUMO
AIM:To evaluate the long-term clinical efficacy of Shotfile software for the myopia patients with presbyopia.METHODS:A total of 43 cases (82 eyes) over the age of 35 myopia patients were treated with laser corneal surgery in our hospital,added Shotfile software at the same time,and followed up for 3a.The uncorrected visual acuity(the distance and near vision),diopter change and visual satisfaction rate were observed at 1,2 and 3a after operation.RESULTS:At 1a after operation,there were 81 eyes (99％) with the uncorrected distance visual acuity reached the preoperative best corrected visual acuity,and 75 eyes (91％) with the uncorrected near visual acuity above 0.66,the average value of the spherical equivalent was (-0.64±0.63)D,the overall satisfaction rate was 91％.At 2a after operation,there were 79 eyes (96％) with the uncorrected distance visual acuity reached the preoperative best corrected visual acuity,and 69 eyes (84％) with the uncorrected near visual acuity above 0.66,the average value of the spherical equivalent was (-0.62±0.59) D,the overall satisfaction rate was 86％.At 3a after operation,There were 77 eyes (94％) with the uncorrected distance visual acuity reached the preoperative best corrected visual acuity,and 62 eyes (76％) with the uncorrected near visual acuity above 0.66,the average value of the spherical equivalent was (-0.55 ± 0.56) D,the overall satisfaction rate was 81％.Intraoperative or postoperative serious complications were not found in all the cases,1 eye of spherical equivalent with-10.0D was found-1.75D back after 1a,respected the willingness of patient for the second correction.CONCLUSION:Shotfile software for the patients myopia with presbyopia is safe and stable in the long-term clinical treatment,and the patient satisfaction is higher,but the near visual ability of some patients may be weakened with the prolongation of time,preoperative communication with patients should be fully.